Intravenous Minophagen (Glycyrrhizin) for Drug-Induced Hepatitis
Intravenous glycyrrhizin preparations, including minophagen (compound glycyrrhizin), are effective and recommended for treating drug-induced liver injury (DILI), with strong evidence showing significant improvements in liver enzyme normalization and histological outcomes.
Evidence-Based Recommendation
Glycyrrhizin preparations have demonstrated clear clinical benefit in DILI treatment through multiple high-quality studies and are now incorporated into treatment guidelines 1. The most compelling recent evidence comes from a 2022 randomized controlled trial showing that compound glycyrrhizin combined with corticosteroids achieved 94.3% sustained biochemical response versus 71.4% with glycyrrhizin alone in chronic DILI 2. Even as monotherapy, a 2022 nationwide database analysis demonstrated that compound glycyrrhizin injections significantly improved ALT normalization (43.42% vs. 24.34%) and AST normalization (63.82% vs. 38.82%) compared to no treatment 3.
Treatment Algorithm by DILI Severity
Acute DILI (First-Line Approach)
- Immediately discontinue the offending drug 4
- Initiate IV glycyrrhizin preparations as hepatoprotective therapy
- Standard dosing based on clinical formulations (compound glycyrrhizin or diammonium glycyrrhizinate)
- Monitor liver enzymes weekly initially
Chronic DILI (>6 months duration)
- Consider combination therapy: Corticosteroids (methylprednisolone with 48-week stepwise dose reduction) plus glycyrrhizin 2
- This approach is particularly effective regardless of whether AIH-like features are present
- Baseline liver biopsy recommended to assess histological severity
- Repeat biopsy at 48 weeks to document histological improvement
Severe DILI with Acute Liver Failure
- Glycyrrhizin may be used as supportive therapy
- List patient for liver transplantation immediately as this remains the definitive lifesaving option 4
- Continue supportive care while awaiting transplant
Mechanisms of Action
Glycyrrhizin works through multiple complementary pathways 5, 6:
- Anti-inflammatory effects: Reduces hepatic inflammation
- Antioxidant protection: Restores depleted glutathione and reduces oxidative stress 7, 8
- Membrane stabilization: Protects hepatocyte integrity
- Anti-apoptotic effects: Prevents programmed cell death
- Mitochondrial protection: Particularly important in acetaminophen toxicity 7
The drug specifically inhibits neuronal nitric oxide synthase (nNOS) activity and reduces protein tyrosine nitration, which are critical pathways in drug-induced hepatotoxicity 7.
Critical Clinical Considerations
Safety Profile
Glycyrrhizin preparations demonstrate excellent safety comparable to no treatment 3. However, monitor for:
- Pseudoaldosteronism: The primary adverse effect, manifesting as hypertension, hypokalemia, and edema 6
- Renal function parameters (though no significant differences observed in clinical trials)
- Drug interactions, particularly with other hepatically metabolized medications
Special Populations
- Hepatocellular injury pattern: Most studied population (71.2% of trial participants) with demonstrated efficacy 2
- Cholestatic DILI: Less evidence, but guidelines support use with careful monitoring 1
- Female patients: Comprise majority of study populations (77.5%) with good response 2
- Patients >40 years: Well-represented in trials with favorable outcomes 2
Timing and Duration
Post-treatment efficacy is established: Glycyrrhizin can be initiated even 90 minutes after hepatotoxic insult and still provide significant benefit 7. This is clinically crucial since most DILI cases present after injury has occurred, not preventively.
- Acute DILI: Continue until biochemical normalization (typically weeks to months)
- Chronic DILI: 48-week protocol when combined with corticosteroids 2
- Monitor time to biochemical normalization as a key efficacy endpoint
Common Pitfalls to Avoid
- Don't delay discontinuation of offending drug: Glycyrrhizin is adjunctive therapy, not a substitute for removing the causative agent 4
- Don't use glycyrrhizin alone in severe acute liver failure: These patients require transplant evaluation 4
- Don't overlook chronic DILI: Patients with persistent elevation >6 months benefit from combination therapy with corticosteroids 2
- Don't assume all herbal supplements are safe: Obtain complete medication history including all supplements 4
Monitoring Parameters
- Baseline: ALT, AST, alkaline phosphatase, bilirubin, INR, albumin
- Weekly initially: ALT and AST to assess response
- Monthly: Complete metabolic panel including electrolytes (for pseudoaldosteronism)
- At 48 weeks for chronic DILI: Repeat liver biopsy to document histological improvement 2
The evidence strongly supports glycyrrhizin preparations as effective, safe, and guideline-recommended therapy for drug-induced hepatitis, with the highest quality recent data showing both biochemical and histological improvements 2, 3.